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Objective: Use of aprotinin has been suspended in cardiac surgery since recent studies reported its risks associ-
ated with mortality and other adverse events. This study was to investigate the safety and efficacy of aprotinin
through a comparison before and after aprotinin was suspended in cardiac surgery.
Methods:We designed a case–control study in two groups of patients who underwent cardiac surgery just before
and after aprotinin was suspended in China. The aprotinin group (n¼ 1699) was defined as operations performed
from June 19, 2007, to December 18, 2007, when aprotinin was used in all the patients. The control group
(n ¼ 2225) was defined as operations performed from December 19, 2007, to June 18, 2008, when aprotinin
was not used. We compared early postoperative outcomes between the two groups.
Results: The aprotinin group had less postoperative blood loss, transfusion requirement, and reoperation for
bleeding. Application of aprotinin did not increase the risk of in-hospital mortality (0.5% vs 1.0%; P ¼ .08)
and other major adverse outcome events, including renal, cardiac, neurologic, and pulmonary complications.
The aprotinin group had a shorter mechanical ventilation time (P¼ .04), a lower rate of delayed mechanical ven-
tilation time (P ¼ .04), and a higher arterial oxygen tension/inspired oxygen fraction ratio in arterial blood gas
analysis (P<.001). Multivariable logistic regression analysis confirmed findings from univariate analysis. After
propensity adjustment for the baseline characteristics, we obtained similar results.
Conclusions: Use of aprotinin in cardiac surgery could reduce blood loss and transfusion requirement significantly
and showed a protective effect on the lungs, but it did not increase the risk of mortality or major complications.Aprotinin, a serine protease inhibitor, has been widely used
in cardiac surgery formore than 10 years, since it was first ap-
proved by the US Food and Drug Administration for use
in high-risk patients requiring coronary artery surgery in
1993. The main purpose of aprotinin is to reduce blood
loss and limit inflammatory responses after cardiopulmonary
bypass (CPB). Many studies1-8 have proved the safety and
efficacy of aprotinin in patients undergoing cardiac surgery.
Therefore, application of aprotinin had been a therapeutic
routine in many cardiac centers. However, Mangano and
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doi:10.1016/j.jtcvs.2009.03.021The Journal of Thoracic and Cassociates9,10 found the use of aprotinin in patients undergo-
ing coronary artery bypass grafting (CABG) to be associated
with higher mortality and increased risk of renal, cerebral,
and cardiac adverse events in both short-term and long-
term studies. These findings and conclusions resulted in con-
troversies in aprotinin use in cardiac surgery all over the
world. Several large-scale retrospective studies focused on
the safety concerns of aprotinin and yielded different
results.11-16 The prospective randomized controlled multi-
center study named BART17 (the Blood Conservation Using
Antifibrinolytics in a Randomized Trial) compared aprotinin
with two other antifibrinolytics in patients undergoing high-
risk cardiac surgery. The aprotinin group had higher 30-day
mortality than the other two groups and the study’s recom-
mendation was to ‘‘preclude its use in patients undergoing
high-risk cardiac surgery.’’ As a result of the BART, the
US Food and Drug Administration suspended the use of
aprotinin in cardiac surgery on November 5, 2007.
Subsequently, the State Food and Drug Administration of
China suspended its use in cardiac surgery on December
19, 2008.
However, several issues or concerns have to be addressed
for the clinical safety of aprotinin. First, most of the enrolled
patients in these studies were white. Ethnic differences exist
in blood coagulation function and fibrinolysis18,19 and in re-
sponses to special drugs such as warfarin.20,21 Doesardiovascular Surgery c Volume 138, Number 4 897
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DAbbreviations and Acronyms
BART ¼ Blood Conservation Using
Antifibrinolytics in a
Randomized Trial
CABG ¼ coronary artery bypass grafting
CI ¼ confidence intervals
CPB ¼ cardiopulmonary bypass
ICU ¼ intensive care unit
KIU ¼ kallikrein international units
PaO2/FIO2 ¼ arterial oxygen tension/
inspired oxygen fraction ratio
aprotinin have the same effect and safety concerns in Asian
populations as in white patients? Second, a relatively lower
dosage of aprotinin was given in Chinese cardiac surgery
than that used in the aforementioned studies. Does a low
dose of aprotinin have fewer safety concerns in cardiac sur-
gery and can the optimal (safe and effective) dosage of apro-
tinin be found? Third, the pivotal BART study focused on
a special cohort of patients who underwent high-risk cardiac
surgery, and its conclusion was to stop the use of aprotinin in
high-risk cardiac surgery. Is this recommendation valid in
low-risk cardiac surgery or in the whole body of patients un-
dergoing cardiac surgery? Fourth, aprotinin is superior to
other antifibrinolytics in reducing blood loss after sur-
gery.9,17 The suspension or permanent withdrawal of aproti-
nin will lead to increased transfusion requirements and
concomitant complications. Do patients benefit more or
less after the suspension of aprotinin in cardiac surgery?
To address these questions, we performed an observa-
tional study in a single cardiac center in China to evaluate
the safety and efficacy of aprotinin in cardiac surgery in
the Chinese population.
METHODS
Study Design
We conducted an observational study based on a policy change in car-
diac surgery: the use of aprotinin in cardiac surgery was suspended in China
on December 19, 2007. We defined two groups of patients who underwent
cardiac surgery during equal periods before and after that date. The aprotinin
group (n ¼ 1699) was defined as consecutive adult patients undergoing
open cardiac surgery from June 19, 2007, to December 18, 2007, during
which period aprotinin was used in all patients. The control group (n ¼
2225) was defined as consecutive adult patients undergoing open cardiac
surgery from December 19, 2007, to June 18, 2008, during which aprotinin
was not used and no other antifibrinolytic medications were given. This
study was performed in the Department of Cardiovascular Surgery, Fuwai
Hospital, Beijing, which is the largest cardiac center in China, with more
than 7000 cardiovascular surgical operations performed per year. During
the study period, the surgical team did not change, the proportions of every
type of operations were almost same, and the perioperativemanagement fol-
lowed the same protocol in the two groups. Clinical baseline characteristics
and postoperative outcomes were collected throughout hospitalization ma-
terials. The study was approved by the ethics committee of Fuwai Hospital.898 The Journal of Thoracic and Cardiovascular SurStudy Population
All the enrolled patients were at least 18 years of age and underwent
open-thorax cardiac surgical procedures with CPB. The cardiac surgical
procedures included the following: CABG, valve replacement or repair, sur-
gery for congenital heart disease, surgery of the aorta, and other cardiac sur-
gical procedures. Patients who required urgent procedures, repeat cardiac
surgery, or combined cardiac surgical procedures were also considered eli-
gible. Infrequent procedures such as heart transplantation and procedures
without CPB were excluded. We excluded 2389 pediatric patients with con-
genital heart disease (who are younger than 18 years and for whom aprotinin
is not routinely used according to the protocol in our center) and 728 oper-
ations without CPB.
Administration of Aprotinin
In the Cardiac Surgery Department of Fuwai Hospital, the maximum
effective regimen of aprotinin was not given. For patients in the aprotinin
group, a test dose of 10,000 kallikrein international units (KIU) of aprotinin
was administered during a 30-minute period after the insertion of a central
venous line and induction of anesthesia. In the absence of an anaphylactic
reaction, the loading dose (1 million–3 million KIU) was given by the anes-
thetist. An additional dose of 2 million KIU was added to the CPB circuit.
The total dosage of aprotinin was 3 to 5 million KIU, with a mean dosage of
3.7  1.2 million KIU. For patients in the control group, neither aprotinin
nor other antifibrinolytic medications were given during the operation.
Outcomes and Definition
Primary outcomes were blood loss, transfusion requirement, and reoper-
ation for bleeding. Blood losswas defined as the blood lost from chest tubes
in the first 24 hours and the second 24 hours after the operation. Transfusion
requirement included the amount of red cells and plasma. Reoperations for
bleeding were designated as those resulting from massive bleeding or car-
diac tamponade within 24 hours after the operation.
Secondary outcomes included in-hospital mortality and major adverse
events. In-hospital mortality was defined as death from any cause after
the operation during hospitalization. Renal dysfunction required a postoper-
ative serum creatinine level of at least 177 mmol/L with an increase over pre-
operative baseline levels of at least 62 mmol/L. The serum creatinine value
selected for analysis was the peak value after the operation. Renal failure
was defined as renal dysfunction requiring dialysis owing to prolonged oli-
guria or anuria. Neurologic complications included new-onset stroke, coma,
and encephalopathy. Stroke was defined as a history of central neurologic
deficit persisting more than 24 hours. Coma was defined as unresponsive
coma lasting more than 24 hours. Encephalopathywas defined as reversible
neurologic deficit (recovery within 72 hours of onset). Low cardiac output
syndromewas defined as a cardiac index lower than 2.0 L $min1 $m2 and
the postoperative need for left ventricular assist device, intra-aortic balloon
pump (IABP), and inotropic support. Pulmonary complications included de-
layed mechanical ventilation time (>24 hours), reintubation owing to respi-
ratory failure, and serious pneumonia, which was diagnosed by sputum
culture and radiograghic findings.
Tertiary outcomes included the length of intensive care unit (ICU) stay,
total mechanical ventilation time, and arterial oxygen tension/inspired oxy-
gen fraction (PaO2/FIO2) ratio in the blood gas analysis 24 hours after the
operation.
Subgroup Analysis
In addition, we divided the patients into subgroups according age, sex,
type of procedure, and risk level to investigate whether aprotinin was an in-
dependent risk factor of mortality, reoperation for bleeding, and composite
complications. The cut point of age subgroup was 65 years old. The high-
risk subgroup in our study was defined as patients undergoing aortic surgery
and repeated surgical procedures, and the low-risk subgroup included all the
primary procedures except aortic surgery.gery c October 2009
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Data of clinical baseline characteristics and postoperative outcomes were
compared statistically. The Student t test and c2 test were used to analyze con-
tinuous variables and categorical variables, respectively, in univariate analy-
ses; means and standard deviations were used for continuous variables and
frequencies for categorical variables. Multivariable logistic regression analy-
ses were used to examine whether use of aprotinin was independently related
to defined postoperative outcomes. Fifteen risk predictors were assessed for
association with outcomes by stepwise methods. Besides aprotinin, predictors
studied included age, weight, sex, emergency operation, left ventricular ejec-
tion fraction, preoperative atrial fibrillation, history of myocardial infarction,
prior open cardiothoracic operations, history of cerebral adverse events, hy-
pertension, diabetes metabolism, history of heart failure, CPB time, aortic
crossclamp time, and preoperative serum creatinine level. All outcomes of in-
terest were as follows: reoperation owing to bleeding, in-hospital mortality,
renal dysfunction, renal failure necessitating dialysis, low cardiac output syn-
drome, intra-aortic balloon pumping after the operation, new-onset neuro-
logic complications, delayed mechanical ventilation time, serious lung
infection, and repeat intubation owing to respiratory failure. Selection bias
not controlled by multivariable regression was assessed with a propensity-
adjustment method. Using logistic regression modeling, we calculated
propensity scores for the use of aprotinin (vs control), including 15 treat-
ment-selection covariates. Multivariable regression was performed with and
without propensity scores as a variable and yielded similar results.
All analyses were performed with SPSS statistical software (version
11.0; SPSS, Inc, Chicago, Ill).
RESULTS
The clinical baseline characteristics of the two groups are
shown in Table 1. The study comprised 3924 patients, 1699
patients in the aprotinin group and 2225 patients in the con-
trol group. The proportion of every type of operation was
similar between the two groups (Figure 1). The control
group had more patients having an emergency operation
(2.5% vs 1.6%; P ¼ .05) and more patients with preopera-
tive atrial fibrillation (18.7% vs 16.1%; P¼ .03). There was
no significant difference between the two groups in other
preoperative and operative characteristics (Table 1).
Blood Loss and Transfusion (Figure 2)
Blood loss in the control group was higher than that in the
aprotinin group for both the first 24 hours (628.1  378.2
mL vs 402.5 267.3 mL; P<.001) and the second 24 hours
(246.4  231.7 mL vs 212.8  209.8; P< .001). Similarly,
the transfusion requirement for red cells (3.2  5.6 units vs
2.6 5.8 units; P¼ .002) and plasma (400.5 724.2 mL vs
317.0 746.0 mL; P<.001) was significantly higher in the
control group. The rate of reoperation for bleeding was
higher in the control group (3.7% vs 2.0%; P¼ .002) (Table
2). Multivariate regression analysis revealed that aprotinin
was an independent predictor of reoperation for bleeding af-
ter adjustment of effects from other covariates (P¼ .002; rel-
ative risk, 0.51; 95% confidence intervals [CI], 0.34–0.78).
After propensity score adjustment, multivariate regression
analysis continued to demonstrate a significant association
between the use of aprotinin and a decreased risk of reoper-
ation for bleeding (Table 3).The Journal of Thoracic and CMortality and Other Outcome Events
A total of 32 (0.8%) patients died during hospitalization
after surgery. The in-hospital mortality was 0.5% in the
aprotinin group as compared with 1.0% in the control group
(P ¼ .08; Table 2). Results of the multivariate regression
analyses showed that aprotinin was not independently asso-
ciated with in-hospital death (P ¼ .14; relative risk, 0.55;
95%CI, 0.24–1.22) (Table 3). However, the aprotinin group
had a lower rate of delayed mechanical ventilation time than
the control group (8.8% vs 10.7%; P ¼ .04). All rates of
other adverse outcome events, including renal dysfunction,
renal failure necessitating dialysis, new-onset neurologic
complications, low cardiac output syndrome, serious pneu-
monia, reintubation owing to respiratory failure, and com-
posite complications, were similar in the two groups. Both
univariate analysis and multivariate logistic regression anal-
ysis obtained consistent results (Tables 2 and 3) Multivariate
logistic regression analysis with or without propensity score
adjustment yielded identical results (Table 3).
Length of ICU Stay
Therewas no significant difference in themean length of stay
in the ICU between the aprotinin group and the control group
(55.8  84.4 hours vs 53.8 7 7.4 hours; P¼ .44) (Table 2).
TABLE 1. Preoperative baseline characteristics of the patients
Characteristic
Aprotinin group
(n ¼ 1699)
Control group
(n ¼ 2225)
P value
(2-tailed)
Age 47.8  17.2 48.0  16.0 .64
Weight 63.6  13.0 64.4  13.4 .08
Male/female 1033/666 1314/911 .27
Hypertension 452 (26.6%) 587 (26.4%) .88
Diabetes mellitus 164 (9.7%) 252 (11.3%) .09
Creatinine (mmol/L) 80.3  30.6 79.9  29.2 .65
History of renal failure 19 (1.1%) 15 (0.7%) .14
Cerebrovascular
events
47 (2.8%) 86 (3.9%) .06
Myocardial infarction 208 (12.2%) 300 (13.5%) .25
Congestive heart
failure
275 (16.2%) 410 (18.4%) .07
Atrial fibrillation 273 (16.1%) 416 (18.7%) .03*
LVEF (%) 60.4  8.7 60.2  8.3 .55
Emergency status 27 (1.6%) 56 (2.5%) .05*
Repeat procedure 67 (3.9%) 65 (2.9%) .08
CPB time (min) 108.8  51.0 110.2  49.9 .38
Aortic crossclamp
time (min)
72.6  36.3 71.2  32.4 .21
CABG 535 (31.5%) 735 (33.0%) .31
Valve disease 511 (30.1%) 636 (28.6%) .31
CHD 397 (23.4%) 473 (21.3%) .12
Aortic disease 115 (6.8%) 164 (7.4%) .47
Other disease 141 (8.3%) 217 (9.8%) .12
LVEF, Left ventricular ejection fraction; CPB, cardiopulmonary bypass; CABG, cor-
onary artery bypass grafting; CHD, congenital heart disease. The Student t test was
used to analyze continuous variables and c2 test was used for categorical variables.
*Statistical significance was set at P< .05.ardiovascular Surgery c Volume 138, Number 4 899
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The mean mechanical ventilation time after operation in
the aprotinin group was significantly shorter than that in
the control group (18.9  45.0 hours vs 22.2  53.6 hours;
P ¼ .04) (Table 2).
Blood Gas Analysis
Arterial blood gas was regularly analyzed 24 yours after
the operation. The aprotinin group had a higher PaO2/FIO2
ratio than the control group (535.2  221.2 vs 505.8
 214.8; P< .001) (Table 2).
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FIGURE 1. Comparison of every type of procedure in the two groups.
CABG, Coronary artery bypass grafting; CHD, congenital heart disease.900 The Journal of Thoracic and Cardiovascular SuSubgroup Analysis
Subgroup analysis showed that the use of aprotinin did
not increase in-hospital mortality and composite complica-
tions. Furthermore, in the male, old-age, and low-risk sub-
groups, aprotinin was associated with a lower mortality.
However, the suspension of aprotinin significantly increased
the rate of reoperation for bleeding in the subgroups of
young-age, male, low-risk, and CABG (Table 4).
DISCUSSION
According to our findings, the use of aprotinin in cardiac
surgery could significantly reduce blood loss and transfusion
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FIGURE 2. Comparison of the postoperative blood loss and transfusion.
Red blood cell (RBC) transfusion: 1 unit ¼ 150 mL.TABLE 2. Comparison of perioperative outcomes
Perioperative outcomes
Aprotinin group
(n ¼ 1699)
Control group
(n ¼ 2225)
P value
(2-tailed)
Blood loss (mL)
First 24 hours 402.5  267.3 628.1  378.2 <.001*
Second 24 hours 212.8  209.8 246.4  231.7 <.001*
Blood transfusion
Plasma (mL) 317.0  746.0 400.5  724.2 <.001*
Red cells (unit) 2.6  5.8 3.2  5.6 .002*
Reoperation for bleeding 34 (2.0%) 83 (3.7%) .002*
In-hospital mortality 9 (0.5%) 23 (1.0%) .08
Renal failure
Renal failure requiring dialysis 21 (1.2%) 22 (1.0%) .46
Renal dysfunction 28 (1.6%) 23 (1.0%) .09
LCOS 327 (19.2%) 467 (21.0%) .18
IABP after operation 13 (0.6%) 22 (1.0%) .46
Neurologic complications 38 (2.2%) 47 (2.1%) .79
Pulmonary complications
Delayed mechanical ventilation time 149 (8.8%) 239 (10.7%) .04*
Reintubation 10 (0.6%) 23 (1.0%) .13
Serious lung infection 16 (0.9%) 19 (0.9%) .77
Composite complications 394 (23.2%) 534 (24.0%) .55
Length of ICU stay (h) 55.8  84.4 53.8  74.4 .44
Mechanical ventilation time (h) 18.9  45.0 22.2  53.6 .04*
PaO2/FIO2 ratio 535.2  221.2 505.8  214.8 <.001*
LCOS, Low cardiac output syndrome; IABP, intra-aortic balloon pump; ICU, intensive care unit; PaO2/FIO2, arterial oxygen tension/inspired oxygen fraction. The Student t test was
used to analyze continuous variables, and the c2 test was used for categorical variables. *Statistical significance was set at P< .05.rgery c October 2009
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Perioperative outcome events
Without propensity score With propensity score
P value Odds ratio (95% CI) P value Odds ratio (95% CI)
Reoperation for bleeding .002* 0.51 (0.34–0.78) .002* 0.51 (0.34–0.78)
In-hospital mortality .14 0.55 (0.24–1.22) .12 0.52 (0.23–1.17)
Renal failure requiring dialysis .58 1.20 (0.64–2.25) .63 1.17 (0.62–2.20)
Renal dysfunction .10 1.60 (0.91–2.80) .13 1.56 (0.88-2.74)
LCOS .42 0.93 (0.79–1.11) .44 0.94 (0.79–1.11)
IABP after operation .27 0.66 (0.32–1.37) .32 0.69 (0.34–1.43)
Neurologic complications .76 1.07 (0.68–1.68) .80 1.06 (0.68–1.67)
Delayed mechanical ventilation time .02* 0.75 (0.60-0.95) .01* 0.75 (0.59–0.94)
Reintubation .08 0.50 (0.23–1.10) .07 0.48 (0.22–1.07)
Serious lung infection .69 1.15 (0.58–2.30) .74 1.13 (0.56–2.25)
Composite complications .95 1.00 (0.85–1.17) .94 0.99 (0.85–1.17)
CI, Confidence intervals; LCOS, low cardiac output syndrome; IABP, intra-aortic balloon pump. *Statistical significance was set at P< .05.A
C
Drequirement and have a protective effect on the lungs, with-
out increasing the risk of mortality or major complications.
This was an observational study conducted in a single car-
diac center of China, and it was not supported by a business
sponsor. This study was initiated by a policy change of sus-
pending the use of aprotinin in patients undergoing cardiac
surgery on December 19, 2007. By that cut point, we ob-
tained two naturally well-matched groups in a relatively
short period. Thus, the selection bias for patient recruitment
between the two groups would be low, although the study
was not a prospective randomized control trial. Therefore,
our study provided a unique opportunity to demonstrate
the effect of aprotinin in cardiac surgery practice.
Themechanisms of aprotinin have been elucidated inmany
studies.22-24 Through its inhibition of multiple mediators (eg,
kallikrein, plasmin), aprotinin attenuates inflammatory re-
sponses, fibrinolysis, and thrombin generation. As a result, it
can protect the organs and reduce bleeding after cardiac sur-The Journal of Thoracic and Cgery. In the present study, blood loss, transfusion requirement,
and rate of reoperation for bleeding after the operation were
significantly increased after the suspension of aprotinin. Our
results showed that aprotinin was effective in reducing bleed-
ing in cardiac surgery, which was the same effect reported in
most prior studies.1,3,9,13,14,25 As to the safety of aprotinin in
cardiac surgery,Chinesepatients as this sample from theAsian
population were investigated to study whether the adverse ef-
fects mentioned by the previous articles would develop after
administration of aprotinin in cardiac surgery. Our results
illustrated that the use of aprotinin did not increase the risk
of in-hospitalmortality and othermajor complications.Of par-
ticular note,mortality in the aprotinin group (0.5%) was lower
than that in the control group (1.0%), although the difference
did not reach statistical significance (P ¼ .08).
In thepresent study, theuseof aprotininwas effective in reduc-
ing blood loss, and it did not create more safety concerns than
those in the control group. These results were notably differentTABLE 4. Multivariate logistic regression analysis of effect of aprotinin in various major subgroups
In-hospital mortality Composite complications Reoperation for bleeding
Major subgroups P value Odds ratio (95% CI) P value Odds ratio (95% CI) P value Odds ratio (95% CI)
Age
65 y (n ¼ 630) .04* 0.21 (0.05–0.93) 1.00 1.00 (0.70–1.43) .08 0.48 (0.21–1.10)
<65 y (n ¼ 3294) .25 0.57 (0.21–1.50) 1.00 1.00 (0.84–1.19) .01* 0.56 (0.35–0.89)
Sex
Male (n ¼ 2347) .04* 0.34 (0.12–0.95) .70 1.04 (0.85–1.27) .003* 0.47 (0.29–0.77)
Female (n ¼ 1577) .71 0.78 (0.21–2.89) .75 0.96 (0.75–1.23) .39 0.72 (0.34–1.52)
Risk level
High risk (n ¼ 399) .78 0.83 (0.23–3.06) .83 1.05 (0.66–1.69) .93 1.04 (0.47–2.28)
Low risk (n ¼ 3525) .05* 0.36 (0.13–0.99) .94 0.99 (0.84–1.17) <.001* 0.42 (0.26–0.68)
Procedures
CABG (n ¼ 1270) .052 0.12 (0.01–1.02) .66 1.07 (0.80–1.41) .006* 0.36 (0.17–0.75)
Valve (n ¼ 1147) .12 0.25 (0.04–1.45) .27 0.86 (0.66–1.12) .07 0.45 (0.19–1.07)
CHD (n ¼ 870) .91 1.11 (0.17–7.23) .45 0.86 (0.59–1.26) .43 0.64 (0.21–1.95)
Aortic (n ¼ 279) .72 1.43 (0.20–10.33) .85 0.95 (0.72–1.43) .84 0.90 (0.34–2.40)
Others (n ¼ 358) .54 0.54 (0.08–3.86) .15 1.47 (0.87–2.48) .62 1.38 (0.39–4.94)
CABG, Coronary artery bypass grafting; CHD, congenital heart disease; CI, confidence intervals; high risk, including aortic surgical procedures and repeated procedures; low risk,
including all the primary procedures except the aortic operation. *Statistically significant difference.ardiovascular Surgery c Volume 138, Number 4 901
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Dfrom findings of recent studies opposing the use of aprotinin in
cardiac surgery.Thepossible reasonswereas follows:First, racial
differencemay partially lead to different results. In the prior stud-
ies, most of the enrolled patients were white, whereas all the pa-
tients enrolled in the present study were Chinese (Asian). It has
been reported that there are racial or ethnic differences in the
blood coagulation function and fibrinolysis system18,19 and dif-
ferences in responses to special drugs such as warfarin.20,21 Until
now, there have been no large-scale studies about aprotinin avail-
able in the Asian population. A different response to aprotinin
may exist betweenwhite andAsian populations. Second, a lower
dose of aprotinin may cause fewer safety concerns. In Chinese
cardiac surgery, aprotinin was given at a relatively lower dosage
than the maximum effective regimens. In the previous studies,
a low dose of aprotinin was effective in reducing blood loss,3,25
and Mangano, Tudor, and Dietzel9 reported that a high dose of
aprotininwas associatedwith an increasedmortality andmorbid-
ity. Theremight be an optimal dose range of aprotinin thatwill be
safe and effective in cardiac surgery. Third, the BART study fo-
cused on a special cohort of patients who underwent high-risk
surgery.Whether aprotinin has the same clinical impact on all pa-
tients undergoing cardiac surgery has not been proved. In this
study, most of the patients were at low risk. Low-risk patients
might benefit from aprotinin without major safety concerns. In
view of these uncertainties of aprotinin, further studies are war-
ranted in different races, operations, and dosages before a final
decision is made about whether to continue or discontinue the
use of aprotinin in cardiac surgery.
The shorter mechanical ventilation time and higher PaO2/
FIO2 ratio in blood gas analysis indicated better respiratory
function in the aprotinin group in this study. It has been re-
ported that aprotinin could decrease lung edema in cardiac sur-
gery.24,26 In this study, aprotinin might protect the lungs
through reducing inflammatory responses from damage after
CPB, and less blood transfusion in the aprotinin group might
also be beneficial to the lungs.
Among 399 patients in the high-risk subgroup, the use of
aprotinin was not associated with an increase of mortality,
composite complications, and reoperation for bleeding.
Although in the low-risk subgroup (n ¼ 3525) aprotinin de-
creased mortality (P ¼ .05; odds ratio, 0.36; 95% CI, 0.13–
0.99) and the rate of reoperation for bleeding (P<.001; odds
ratio, 0.42; 95% CI, 0.26–0.68), it was not associated with
composite complications (P ¼ .94; odds ratio, 0.99; 95%
CI, 0.84–1.17). Therefore, this indicated that its use in low-
risk patients was safe and effective.
The present study does have some limitations. First, it was
a retrospective observational study in a single center, and its
patient allocation was based on a policy change. However,
there was no significant difference in most of the preopera-
tive characteristics. Second, although all the patients under-
went surgical procedures within the restricted consecutive
12 months, a time-related selection bias might exist between
the two groups. Third, all the enrolled patients were Chinese,902 The Journal of Thoracic and Cardiovascular Surand the results may be relevant and applicable only in the
Chinese or Asian population.
In conclusion, in this observational cohort study of Chi-
nese patients, use of aprotinin in cardiac surgery could sig-
nificantly reduce blood loss and transfusion requirement
and have a protective effect on the lungs, without increasing
the risk of mortality or major complications. Should aproti-
nin be totally suspended or replaced in cardiac surgery in
a precipitous manner? Further large well-designed and
well-constructed randomized controlled trails in different
races, dosages, and cardiac operations will be required to
give a definitive answer to this question.
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